# US 2025/0137050 A1 · Methods and compositions for determining risk of autism spectrum disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0137050 A1
- Document ID: US20250137050A1
- Status: Published application
- Kind: A1
- Application number: 18/683,978
- Filed: 2022-06-17
- Published: 2025-05-01
- Earliest claimed: 2021-08-18
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Janine M. LaSalle
- Web page: https://patentgrep.com/patent/US20250137050A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/1709: {from mammals}
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/6869: Methods for sequencing
- C12Q 2600/154: Methylation markers
- G01N 2800/28: Neurological disorders
- G01N 2800/7038: Hypoxia
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described are methods for identifying an ASD risk gene, NHIP, and methods for determining the risk of an offspring for developing an ASD. A common structural variant disrupting the proximity of NHIP to a fetal brain enhancer was associated with NHIP expression and methylation levels and ASD risk, demonstrating a common genetic influence. NHIP is a novel environmentally-responsive ASD risk gene relevant to brain development in a previously under characterized region of the human genome.

## Claims

### Claim 1

A method for determining a risk of an offspring for developing an autism spectrum disorder (ASD), the method comprising:
detecting in a biological sample obtained from the offspring, mother or potential mother of the offspring expression and/or DNA methylation of a neuronal hypoxia inducible, placental associated (NHIP) gene, wherein decreased expression and/or decreased methylation of the NHIP gene compared to a control sample indicates an increased risk of the offspring for developing an ASD.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises obtaining a biological sample from the mother or potential mother.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological sample is selected from the group consisting of blood, serum, plasma, or saliva from the mother, and placenta, cord blood, blood, saliva and brain from the offspring.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mother or potential mother has a child with an ASD.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mother or potential mother has a familial history of ASD.

### Claim 6 (depends on 1)

The method of claim 1, wherein the offspring is a fetus or child.

### Claim 7 (depends on 1)

The method of claim 1, wherein the control sample is selected from a mother or potential mother having an offspring without an ASD or an offspring exhibiting typical development.

### Claim 8 (depends on 1)

The method of claim 1, wherein the detecting step comprises detecting DNA methylation of the NHIP genetic locus, the chr22q13.33 hypomethylated block, or both.

### Claim 9 (depends on 8)

The method of claim 8, wherein lower DNA methylation levels indicates an increased risk of the offspring for developing an ASD.

### Claim 10 (depends on 1)

The method of claim 1, wherein detecting expression of the NHIP gene comprises detecting an RNA expressed by the NHIP gene or detecting a peptide encoded by the RNA.

### Claim 11 (depends on 10)

The method of claim 10, wherein the RNA is transcribed from an open reading frame comprising the DNA sequence
(SEQ ID NO: 2)
ATGGTGAGAGGAGAGGCCACCGCACGAACGGAAGAAGCGATGGAGACGG
TCTTTACGACC.

### Claim 12 (depends on 10)

The method of claim 10, wherein detecting an RNA expressed by the NHIP gene is selected from amplifying the RNA, quantifying the RNA, or sequencing the RNA.

### Claim 13 (depends on 10)

The method of claim 10, wherein detecting a peptide encoded by the RNA is selected from i) contacting the peptide with a primary antibody that binds the peptide and detecting the primary antibody with a labeled secondary antibody, ii) linking the peptide to a detectable label, or iii) by immunostaining.

### Claim 14 (depends on 10)

The method of claim 10, wherein the peptide comprises the amino acid sequence MVRGEATARTEEAMETVFTT (SEQ ID NO:1).

### Claim 15 (depends on 1)

The method of claim 1, further comprising administering a vitamin to the mother or potential mother if the mother is homozygous for a structural variant inserted about 15 Kbp upstream from the start site of the chr22q13.33 hypomethylated block.

### Claim 16 (depends on 15)

The method of claim 15, wherein the vitamin is administered during the first month of pregnancy.

### Claim 17 (depends on 15)

The method of claim 15, wherein the vitamin comprises a, one or more, or a plurality of dietary methyl group(s).

### Claim 18 (depends on 1)

The method of claim 1, wherein the NHIP gene is hypomethylated.

### Claim 19 (depends on 1)

The method of claim 1, wherein the biological sample is homozygous for a structural variant insertion (chr22: 49029657, hg38) upstream of the 22q13.33 locus.

### Claim 20

A method for detecting an NHIP peptide in a subject, the method comprising:
obtaining a biological sample from the subject; and
detecting the presence of the NHIP peptide by contacting the biological sample with an anti-NHIP antibody and detecting binding between the NHIP peptide and the antibody.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject is a mother or potential mother of an offspring at risk for developing an ASD.

### Claim 22

A method for preventing an autism spectrum disorder (ASD) in an offspring, the method comprising:
administering a vitamin to the mother of the offspring before and/or during pregnancy, wherein the mother has decreased expression and/or DNA methylation of the NHIP gene in a biological sample compared to a control sample.

### Claim 23

A method for preventing or reducing a risk of an offspring for developing an autism spectrum disorder (ASD), the method comprising:
i) selecting a mother or potential mother of the offspring, wherein the mother or potential mother is selected based on having decreased expression and/or DNA methylation of the NHIP gene in a biological sample compared to a control sample; and
ii) administering a vitamin to the mother or potential mother before and/or during pregnancy, thereby preventing or reducing the risk that the offspring develops an ASD.

### Claim 24 (depends on 20)

The method of claim 20, wherein the biological sample is selected from the group consisting of blood, serum, plasma, or saliva from the mother, and placenta, cord blood, blood, saliva and brain from the offspring.

### Claim 25 (depends on 22)

The method of claim 22, wherein the control sample is selected from a mother or potential mother having an offspring without an ASD or an offspring exhibiting typical development.

### Claim 26

A method for preventing or reducing a risk of an offspring for developing an autism spectrum disorder (ASD), the method comprising:
administering a therapeutically effective amount of an NHIP gene, an NHIP RNA, or an NHIP peptide, to the mother of the offspring before and/or during pregnancy, thereby preventing or reducing the risk of the offspring for developing an ASD.

### Claim 27

A plasmid or vector comprising the NHIP gene, or DNA encoding an NHIP RNA or peptide.

### Claim 28 (depends on 27)

The plasmid or vector of claim 27, further comprising nucleic acid sequences that regulate transcription and/or translation of the NHIP RNA.

### Claim 29 (depends on 27)

An in vitro method for increasing cell proliferation, comprising transfecting a cell with the plasmid or vector of claim 27.

### Claim 30 (depends on 27)

A method for regulating gene expression, comprising transfecting a cell with the plasmid or vector of claim 27, and detecting differential expression of one or more genes.

### Claim 31

An isolated peptide comprising an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:1.

### Claim 32 (depends on 31)

A fusion protein comprising the peptide of claim 31.

### Claim 33

A kit comprising reagents for detecting expression of an NHIP RNA or NHIP peptide.

### Claim 34

An array comprising one or more nucleic acid sequences or probes that are capable of hybridizing to an NHIP RNA.

### Claim 35

An array comprising one or more agents that bind to an NHIP peptide immobilized on a solid support.

### Claim 36 (depends on 35)

The array of claim 35, wherein the one or more agents comprise an antigen binding protein that specifically binds to the NHIP peptide.

### Claim 37

A method for sequencing an NHIP gene sequence, comprising amplifying all or part of an NHIP gene from a biological sample obtained from a subject using a set of primers to produce amplified nucleic acid; and sequencing the amplified nucleic acid.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject is a mother or potential mother of an offspring at risk for developing an ASD.
